Stromal cell-derived factor-1 (SDF-1) validation using equine serum, plasma, and synovial fluid  by Brown, M.P. et al.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S71In a subset of 51 patients (25 male, 26 female, aged 32-56 yrs) the
degree of cartilage lesionwas assessed by an orthopedic surgeon on the
Outerbridge (0-IV) and VAS (0-10) scales in the medial femoral, medial
tibial and patellofemoral compartments. The clinical status of OA
patients was established by KOOS questionnaire (self-assessment) and
by four performance tests (up & go, raising from low chair, stairs-
stepping, 30 m walk).
The immunoassay used was C2C-HUSA (IBEX, Canada) that measures
the C2C neoepitope fragments present in human urine samples. For
statistical data analyses, T-test andSpearman’s rank correlationwereused.
Results: The uC2C values were signiﬁcantly higher for patients with
tibial or femoral lesion degree 2 or higher both at baseline and 3 yrs
after surgery (Fig. 1, B and 3 yrs).uC2C/crea at baseline and 3 yrs later 
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Fig. 1. Output of uC2C juxtaposed to different degrees of lesion in medial
tibial cartilageExcretion of u-C2C correlated positively with knee symptoms as well as
with limitations of everyday and demanding recreative (Sp/Rec) activ-
ities (Table 1).Table 1
Correlations between urinary C2C and results of KOOS questionnaire in female
patients
KOOS subscales, females uC2C expressed in
pg/ml urine
in ng/mmol creatinine
Knee symptoms 107 -0.267 0.005 -0.38 0.00005
knee pain 107 -0.272 0.005 -0.411 0.00001
limitations in ADL 107 -0.321 0.001 -0.464 0.0000005
limitations in Sp/Rec 105 -0.433 0.000004 -0.553 1E-09
Quality of life 107 -0.337 0.0004 -0.512 0.00000002Higher output of uC2C correlates with decline of the functional abilities
of lower limb. In both cases the correlations were stronger when uC2C
was expressed in ng/mmol creatinine (Tables 1, 2).Table 2
Correlations between urinary C2C and results of lower limb performance tests
Performance tests Valid
(N)
uC2C expressed in
pg/ml urine
uC2C expressed in
ng/mmol creatinine
Spearman
(R)
p-value Spearman
(R)
p-value
UP&GO, sec 107 0.304 0.001 0.415 0.000009
Up from low chair, cm 106 0.372 0.00008 0.525 0.000000008
Step up left leg, cm 107 -0.354 0.0001 -0.448 0.000001
Step up right leg, cm 107 -0.36 0.0001 -0.484 0.0000001
30 m walk, sec 107 0.238 0.014 0.405 0.00001Conclusions:
1. Signiﬁcantly higher excreation of uC2C is associated with grade 2þ
cartilage lesion in knee joint.
2. Highly signiﬁcant correlation appears between increased uC2C out-
put and decline in the clinical parameters of the lower limb.
3. The above correlations are stronger when uC2C is expressed in ng/
mmol creatinine.
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Purpose: Stromal cell-derived factor-1 has been measured in syno-
vial ﬂuid (SF) and/or serum in humans and guinea pigs with OA. A
guinea pig study showed large increases in SF concentrations in
animals with primary OA and post-traumatic OA. Similarly, SF from
human OA patients had higher SDF-1 concentrations compared to
controls. Synovial ﬂuid SDF-1 concentrations, but not serum con-
centrations, in human patients with knee OA were shown to be
closely related with radiographic severity of OA. However, serum
concentrations were greater from OA patients when compared to
controls. Combined, these studies demonstrate that SDF-1 concen-
trations in serum or SF may distinguish OA patients from normal
controls. Based on these reports, it seems logical that the SDF-1
assay has the potential to help diagnose, predict, and monitor OA
changes in horses since the horse is a good translational model of
OA for biomarker evaluation. The purpose of this study was to val-
idate the use of the SDF-1 immunoassay in equine serum, plasma,
and SF.
Methods: To validate the SDF-1 immunoassay (Quantikine Human
SDF-1a Immunoassay, R&D Systems), plates from the same lot number
were used to minimize variation. Fresh serum, plasma, and SF were
collected aseptically from 6 normal Thoroughbred horses (6 geldings, 11
to 12 years of age) and samples for each ﬂuid were pooled together for
further analysis. Pooled serum, plasma, and SF samples were spiked
with a known amount of standard to create high (3000 pg/ml), medium
(1000 pg/ml), and low (200 pg/ml) quality control (QC) samples. All QC
samples within each ﬂuid were also pooled together to create a mixed
QC sample (mQC). Fresh pooled, QC, andmQC samples were analyzed at
neat, 1:2, 1:4, and 1:8 dilutions to determine precision, accuracy, line-
arity of dilution, parallelism, percent recovery, and stability of SDF-1
within each ﬂuid. Samples were analyzed in duplicate 3 times within a
plate (intra-assay variability) and across 3 plates (inter-assay varia-
bility). To analyze stability of SDF-1, fresh pooled samples were ana-
lyzed immediately after sample collection, as well as after 24 hours at
room temperature, after 24 hours at 4C, and after 1 to 4 freeze-thaw
cycles at -80C.
Results: Serum samples exhibited a mean intra-assay coefﬁcient of
variation (CV) of 7.5% and inter-assay CV of 10.1%. Plasma samples
exhibited a mean intra-assay CV of 7.8% and inter-assay CV of 13.5%.
Synovial ﬂuid samples exhibited a mean intra-assay CV of 7.6% and
inter-assay CV of 10.3%. The limit of detection for serum was 157.0 pg/
ml,161.2 pg/ml for plasma, and 128.5 pg/ml for SF. All diluted samples in
all ﬂuids demonstrated parallelism to the standard curve. Linearity was
demonstrated for serum and plasma at all dilutions, whereas SF dem-
onstrated linearity for 1:2 and 1:4 dilutions, but not for 1:8 dilutions
(recovery between 56 to 90% of neat samples). Recovery of spiked
samples in the region of the standard curve where all equine samples
congregated was 87% for serum, 95% for plasma, and 71% for SF. When
stored at room temperature, or at 4C for 24 hours, all ﬂuids demon-
strated minimal loss of stability. For serum and plasma, loss in stability
was< 10% of the ﬁrst freeze thaw out to 4 freeze thaw cycles, and for SF,
loss in stability was <10% of the ﬁrst freeze thaw out to 3 freeze thaw
cycles.
Conclusions: Serum and plasma SDF-1 concentrations are com-
parable to each other, whereas SF has more matrix effects at higher
dilutions. Overall, our results demonstrate that the SDF-1 immuno-
assay (Quantikine Human SDF-1a Immunoassay) is a reproducible
and valid assay for use with equine serum, plasma, and synovial
ﬂuid.
